Association of CAD, a multifunctional protein involved in pyrimidine synthesis, with mLST8, a component of the mTOR complexes
- Akio Nakashima†1,
- Ippei Kawanishi†1, 2,
- Sumiko Eguchi1,
- Eugene Hsin Yu1, 3,
- Satoshi Eguchi1, 4,
- Noriko Oshiro1, 5,
- Ken-ichi Yoshino1,
- Ushio Kikkawa1Email author and
- Kazuyoshi Yonezawa^1
© Nakashima et al.; licensee BioMed Central Ltd. 2013
Received: 22 March 2013
Accepted: 15 April 2013
Published: 18 April 2013
mTOR is a genetically conserved serine/threonine protein kinase, which controls cell growth, proliferation, and survival. A multifunctional protein CAD, catalyzing the initial three steps in de novo pyrimidine synthesis, is regulated by the phosphorylation reaction with different protein kinases, but the relationship with mTOR protein kinase has not been known.
CAD was recovered as a binding protein with mLST8, a component of the mTOR complexes, from HEK293 cells transfected with the FLAG-mLST8 vector. Association of these two proteins was confirmed by the co-immuoprecipitaiton followed by immunoblot analysis of transfected myc-CAD and FLAG-mLST8 as well as that of the endogenous proteins in the cells. Analysis using mutant constructs suggested that CAD has more than one region for the binding with mLST8, and that mLST8 recognizes CAD and mTOR in distinct ways. The CAD enzymatic activity decreased in the cells depleted of amino acids and serum, in which the mTOR activity is suppressed.
The results obtained indicate that mLST8 bridges between CAD and mTOR, and plays a role in the signaling mechanism where CAD is regulated in the mTOR pathway through the association with mLST8.
Target of rapamycin (TOR) is a serine/threonine protein kinase genetically conserved among species from yeast to mammal, which belongs to the phosphatidylinositol 3-kinase-related kinase family among the kinome, and controls cell growth, proliferation, and survival. In mammal, mechanistic TOR (mTOR) exists as two independently regulated hetero-oligomeric complexes with common and respective partners, called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), that are apparently sensitive and insensitive to rapamycin, respectively . mTORC1, that contains raptor, mLST8 also named as GβL, and DEPTOR, directly phosphorylates the substrates such as S6 kinase, 4E-BP1, and PRAS40, and links signals including amino acids, growth factors, and energy to regulate various cellular functions such as protein synthesis, transcription, metabolism, and autophagy. Rheb, a small GTPase, activates mTORC1 as the GTP-bound form, and tuberous sclerosis complex (TSC) gene products, TSC1 and TSC2, form a dimer to function as a GTPase activating protein toward Rheb and thereby negatively regulate mTORC1. mTORC2, on the other hand, has rictor, mLST8, mSin1, DEPTOR, and Protor, and mediates growth factor signals but not those of nutrients to catalyze the phosphorylation of some AGC protein kinases such as Akt, SGK, and PKCα [2, 3].
mLST8 is a 36-kDa protein having seven WD40 repeats, and is a common partner of mTORC1 and mTORC2 [4, 5]. mLST8 appears to bind to the catalytic domain of mTOR , and the overexpression and knockdown of mLST8 suggested its positive function in mTORC1. The following studies using mice lacking mLST8 showed that this protein is required for assembly of mTOR and rictor, but not for the mTOR-raptor interaction, and that mLST8 has a role for mTORC2 rather than for mTORC1 . The precise role of mLST8, thus, still remains unclear especially in mTORC1.
In this study, we isolated the binding proteins to mLST8 by analyzing the proteins that co-immunoprecipitated with FLAG epitope-tagged mLST8 from the transfected HEK293 cells, and identified one of them as CAD, a multifunctional protein with a deduced molecular mass of 243 kDa composed of the distinct regions in a single polypeptide: carbamoyl phosphate synthetase II (CPSase), aspartate transcarbamoylase (ATCase), and dihydroorotase (DHOase), which catalyze each of the initial three steps in de novo pyrimidine synthesis [8, 9]. CPSase is the first and rate-limiting step for the nucleotide synthesis and allosterically activated and inhibited by phosphoribosyl 5’-pyrophosphate and uridine nucleotides, respectively. Moreover, CAD is regulated by the phosphorylation reaction with different protein kinases such as MAP kinase , PKA , and PKC . Very recently, CAD has been reported to be phosphorylated by S6 kinase in the downstream of mTORC1 [13, 14].
Here, we describe the association of CAD with mLST8, which provides a physical environment where CAD is regulated by the protein phosphorylation reaction in the mTOR signaling pathway, and an evidence that the CAD enzymatic activity is controlled in the mTOR-signaling pathway.
The FLAG-tagged expression vectors of the wild type mLST8 (FLAG-mLST8) and its mutants replacing Gly150 by Asp (G150D), Gly192 by Asp (G192D), and Phe320 by Ser (F320S) constructed in pCMV5 were kindly provided by Dr. Joseph Avruch (Massachusetts General Hospital, USA). The mLST8 mutant replacing Ala182 by Asp (A182D) was generated using a QuikChange site-directed mutagenesis kit (Stratagene). The expression vector of HA-tagged mTOR was constructed as described previously . The cDNA encoding CAD was cloned by the successive polymerase chain reactions using mouse brain cDNAs (Quick-Clone, Clontech) as template. The primers were designed to amplify CAD in three portions according to the DNA sequence in the database (accession no. NM_023525), and the products were assembled into pcDNA3 with myc-epitope tag. The deletion mutants of CAD, GLN/CPS (amino acids 1–1456), GLN/CPS’ (amino acids 1–1461), DHO/ATC (amino acids 1457–2225), DHO/ATC’ (amino acids 1462–2225), GLN (amino acids 1–373), CPS-A (amino acids 391–939), CPS-B (amino acids 929–1461), DHO (amino acids 1457–1788), and ATC (amino acids 1911–2225) were generated in the pcDNA3-myc vector.
The anti-FLAG (M2) and anti-myc (9E10) antibodies were purchased from Sigma, and the anti-HA antibodies (12CA5 and 3F10) were from Roche. The polyclonal antibody against mLST8 was generated as described . The rabbit polyclonal anti-peptide antibody recognizing CAD was produced by the antibody service of Immuno-Biological Laboratories against the synthetic peptide EVDSDPRAAYFRQAENG (amino acids 2194–2210). Normal rabbit and mouse globulin were obtained from Santa Cruz Biotechnology. The horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit antibodies were obtained from Jackson ImmunoResearch Laboratories and Bio-Rad, respectively.
Cell culture and transfection
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) containing 10% fetal bovine serum (FBS) (Gibco BRL) at 37°C in a 5% CO2 incubator. The cells were transfected with expression vectors by lipofection using lipofectamine (Invitrogen) according to the manufacturer’s protocol. For starvation of the cells, they were first incubated in DMEM without FBS for 16 h, and further incubated for 2 h with different culture media .
The following procedures were carried out at 0-4°C. The cells were washed with ice-cold with Dulbecco’s phosphate-buffered saline, and lysed with Buffer A (20 mM Tris–HCl at pH 7.5, 120 mM NaCl, 1 mM EDTA, 5 mM EGTA, 20 mM β-glycerophosphate, 0.3% CHAPS, 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin, 2 μg/ml leupeptin, and 1 mM dithiothreitol). The supernatant was recovered by centrifugation at 15,000 × g for 25 min, and was incubated for 2 h with Protein G-Sepharose (GE Healthcare) coupled with each antibody, and the immunoprecipitate was washed three times with Buffer A.
The immunoprecipitate was obtained by the anti-FLAG antibody from the HEK293 cells transfected with FLAG-mLST8. The resin was eluted with Buffer A containing 200 μg/ml FLAG peptide (Sigma), and the proteins were separated by SDS-PAGE and visualized by silver staining. Each protein band was recovered and mass spectrometric analysis was carried out essentially as described .
The cell extracts and immunoprecipitates were separated by SDS-PAGE, and the proteins were transferred to a polyvinylidene difluoride membrane and subjected to immunoblotting using each primary antibody. After incubation with the HRP-conjugated secondary antibodies, detection of the proteins was carried out by the chemiluminescence reaction.
mTOR kinase assay
The mTOR kinase assay was performed as previously described [16, 17]. Briefly, myc-CAD was immunoprecipitated from the transfected HEK293 cells and eluted from the resign with 300 μg/ml myc peptide (Fujiya, Japan). The immunoprecipitates obtained by the anti-HA antibody from the HEK293 cells transfected with either HA-mTOR or the empty vector were incubated with purified CAD in the reaction mixture containing 10 mM HEPES at pH7.4, 50 mM β-glycerophosphate, 50 mM NaCl, 10 mM MnCl2, 100 μM ATP, and 370 kBq of [γ-32P]ATP. After the incubation for 30 min at 30°C, the samples were separated by SDS-PAGE, transferred onto a polyvinylidene difluoride membrane, and analyzed by autoradiography.
CPSase activity assay
The CPSase activity of the immunoprecipitated myc-CAD was measured essentially as described [18, 19]. Briefly, HEK293 cells were transfected with the myc-CAD expression vector, cultured under the different conditions, and lysed with Buffer A containing 20 mM NaF, 10 mM p-nitrophenyl phosphoric acid, 30% dimethylsulfoxide, and 5% glycerol. The immunoprecipitate with the anti-myc antibody was washed with 100 mM Tris–HCl at pH 8.0 containing 100 mM KCl, 7.5% dimethylsulfoxide, and 2.5% glycerol, and then incubated for 20 min at 37°C with 500 μl of the reaction mixture containing 100 mM Tris–HCl at pH 8.0, 100 mM KCl, 7.5% dimethylsulfoxide, 2.5% glycerol, 1 mM dithiothreitol, 3.5 mM glutamine, 20.2 mM aspartate, 1.5 mM ATP, 200 mM phosphoribosyl 5’-pyrophosphate, 3.5 mM MgCl2, and 5 mM [14C]NaHCO3 (118 MBq/mmol). The reaction was stopped by the addition of 500 μl of 40% trichloroacetic acid, and the tubes were heated at 95°C for 3 h. The incorporation of the 14C radioactivity into the acid stable materials was then measured by liquid scintillation counting, and the relative activity in each immunoprecipitate was normalized to the amount of immunoprecipitated myc-CAD detected by immunoblot.
The result is expressed as the mean ± SD of data obtained from quadruplicate experiments. Statistical analysis was performed using a paired Student t-test, and a P value less than 0.01 was considered statistically significant.
Identification of CAD as an mLST8-binding protein
The binding region of CAD with mLST8
The binding of mLST8 with CAD and mTOR
The measurement of the CPSase activity
In this study, we identified CAD as a binding protein of mLST8. CAD was also detected in the screening of the binding proteins of FLAG-raptor, but the association was weaker than that with FLAG-mLST8 (data not shown). It is thus reasonable to assume that CAD associates with mTORC1 including raptor through mLST8. As mLST8 and raptor, however, both contain WD-40 repeats known to act as a site for protein-protein interaction , it is difficult to exclude the possibility that these two proteins recognize CAD, independently. Concerning the interaction between CAD and mLST8, the results obtained suggest that CAD has more than one region for the recognition of mLST8. It might be possible that the CAD fragments interact with endogenously expressed CAD and the CAD complexes thus generated associate with mLST8, because CAD forms oligomers [8, 9]. On the other hand, mLST8 point mutants having little binding activity with mTOR still associated with CAD. Therefore, mLST8 may bridge between mTOR and CAD, and CAD binds to mLST8 in multiple ways.
We next examined the possibility that CAD is a substrate for mTORC1, because CAD is known to be phosphorylated by some protein kinases [10–12]. The in vitro phosphorylation of CAD was, however, not detected after the incubation with the mTOR immunoprecipitated from the transfected cells. Very recently, Robitaille et al. have carried out the quantitative phosphoproteomics of the mTOR targets in the cells lacking raptor, and concluded that mTOR1 indirectly phosphorylates and regulates CAD: CAD is phosphorylated by S6 kinase at Ser1859 and thereby pyrimidine synthesis is stimulated. Ben-Sahra et al., on the other hand, have identified Ser1859 and Ser1900 as the phosphorylation sites in CAD. They indicate that the modification of Ser1900 is stable but that of Ser1859 is stimulated by insulin in a manner sensitive to rapamycin, and propose that S6 kinase is responsible for the phosphorylation of Ser1859. These two studies indicate that CAD is controlled by the S6-kinase-mediated phosphorylation, but the practical interaction of CAD with mTOR1 has not been analyzed. Taken the available evidence together, it is reasonable to conclude that CAD associated with mTORC1 through mLST8 is not phosphorylated directly by mTOR, but is recognized by S6 kinase that is activated by mTORC1. It is interesting to examine the possibility that the binding proteins to mLST8 are phosphorylated by S6 kinase.
Ser1859 was identified as a phosphorylation site by S6 kinase [13, 14], but this residue as well as Ser1406 have been shown to be the PKA sites in CAD . CAD is, in addition, phosphorylated at Thr456 by MAP kinase  and at Ser1873 by PKC . It is appropriate that CAD is phosphorylated in different signaling pathways by each upstream protein kinase, because the deno nove pyrimidine synthesis is the metabolic reactions critical for the cells. Moreover, CAD is regulated in coordinated manners through the phosphorylation by different protein kinases: MAP kinase and PKA phosphorylate CAD in a mutually antagonistic manner , and the PKC-dependent phosphorylation enhances the MAP kinase-mediated CAD activation . It is thus important to analyze the regulation mechanisms of CAD from a wide point of view.
Concerning the de novo pyrimidine synthesis, Ben-Sahra et al. have showed the regulation of the de novo pyrimidine synthesis through mTOR by comparing the metabolites in TSC2-deficient and control cells labeled with 15 N-glutamine. Robitaille et al. have employed HeLa cells metabolically labeled with the 15 N-glutamine and reported the increase of dihydroorotate, orotate, and UTP after depletion and stimulation with both serum and amino acids. We revealed that the CPSase activity of the immunoprecipitated CAD recovered from the amino acid-depleted cells, in which the mTORC1 activity is suppressed, is decreased by the in vitro assay using [14C] NaHCO3, indicating the contribution of the mTOR complex in the regulation of the CAD activity. These results are compatible with those reported [13, 14] and support the direct regulation of CAD by S6 kinase, but the CPSase activity, in this study, was not enhanced by serum stimulation. It is not clear why the CPSase activity was insensitive to serum stimulation. Further studies are necessary to clarify the regulation mechanisms of CAD through the phosphorylation reaction by the protein kinases.
CAD has been shown to bind with other proteins such as Rad9  and androgen receptor . Rad9 plays a role in the DNA damage checkpoint response as a damage sensor, and the binding of Rad9 to the CPSase domain stimulates the CPSase activity, suggesting the relationship between the DNA damage response and pyrimidine synthesis. Androgen receptor shows a facilitated nuclear localization and an enhanced transcriptional activity by the interaction with CAD, but the role of this nuclear receptor in nucleotide synthesis is not known. It is interesting to know the relationship between mTORC1 and these CAD binding proteins.
The evidences obtained indicate that mTORC1 is involved in the regulation of the pyrimidine nucleotide synthesis. The precise studies of mTORC1 and CAD will bring key observation to clarify the interplay between the synthesis of the proteins and nucleotides, which are critical for the proliferation of the cells.
The results obtained indicate that mLST8 bridges between CAD and mTOR. CAD is not a direct phosphorylation substrate of mTOR, but the association of CAD with mLST8 provides a physical environment where CAD is regulated through the phosphorylation reaction in the mTORC1-signaling pathway.
Authors thank Joseph Avruch for providing mLST8 constructs and discussions. This work was supported in part by research grants from the Scientific Research Funds of the Ministry of Education, Culture, Sports, Science and Technology of Japan and CREST, Japan Science and Technology Agency.
- Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell. 2006, 124: 471-484. 10.1016/j.cell.2006.01.016.View ArticlePubMedGoogle Scholar
- Avruch J, Long X, Lin Y, Ortiz-Vega S, Rapley J, Papageorgiou A, Oshiro N, Kikkawa U: Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem Soc Trans. 2009, 37: 223-226. 10.1042/BST0370223.View ArticlePubMedGoogle Scholar
- Zoncu R, Efeyan A, Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011, 12: 21-35. 10.1038/nrm3025.PubMed CentralView ArticlePubMedGoogle Scholar
- Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004, 6: 1122-1128. 10.1038/ncb1183.View ArticlePubMedGoogle Scholar
- Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004, 14: 1296-1302. 10.1016/j.cub.2004.06.054.View ArticlePubMedGoogle Scholar
- Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM: GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003, 11: 895-904. 10.1016/S1097-2765(03)00114-X.View ArticlePubMedGoogle Scholar
- Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM: Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC alpha but not S6K1. Dev Cell. 2006, 11: 859-871. 10.1016/j.devcel.2006.10.007.View ArticlePubMedGoogle Scholar
- Huang M, Graves LM: De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci. 2003, 60: 321-336. 10.1007/s000180300027.View ArticlePubMedGoogle Scholar
- Evans DR, Guy HI: Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004, 279: 33035-33038. 10.1074/jbc.R400007200.View ArticlePubMedGoogle Scholar
- Graves LM, Guy HI, Kozlowski P, Huang M, Lazarowski E, Pope RM, Collins MA, Dahlstrand EN, Earp HS, Evans DR: Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature. 2000, 403: 328-332. 10.1038/35002111.View ArticlePubMedGoogle Scholar
- Sigoillot FD, Evans DR, Guy HI: Growth-dependent regulation of mammalian pyrimidine biosynthesis by the protein kinase A and MAPK signaling cascades. J Biol Chem. 2002, 277: 15745-15751. 10.1074/jbc.M201112200.View ArticlePubMedGoogle Scholar
- Sigoillot FD, Kotsis DH, Masko EM, Bame M, Evans DR, Evans HI: Protein kinase C modulates the up-regulation of the pyrimidine biosynthetic complex, CAD, by MAP kinase. Front Biosci. 2007, 12: 3892-3898. 10.2741/2358.View ArticlePubMedGoogle Scholar
- Robitaille AM, Robitaille S, Shimobayashi M, Cornu M, Fava LL, Moe S, Prescianotto-Baschong C, Sauer U, Jenoe P, Hall MN: Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science. 2013, 339: 1320-1323. 10.1126/science.1228771.View ArticlePubMedGoogle Scholar
- Ben-Sahra I, Howell JJ, Asara JM, Manning BD: Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013, 339: 1323-1328. 10.1126/science.1228792.PubMed CentralView ArticlePubMedGoogle Scholar
- Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I, Avruch J: Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem. 1997, 272: 26457-26463. 10.1074/jbc.272.42.26457.View ArticlePubMedGoogle Scholar
- Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J, Yonezawa K: Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells. 2004, 9: 359-366. 10.1111/j.1356-9597.2004.00727.x.View ArticlePubMedGoogle Scholar
- Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, Kikkawa U, Yonezawa K: The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem. 2007, 282: 20329-20339. 10.1074/jbc.M702636200.PubMed CentralView ArticlePubMedGoogle Scholar
- Tatibana M, Ito K: Control of pyrimidine biosynthesis in mammalian tissues. I. Partial purification and characterization of glutamine-utilizing carbamyl phosphate synthetase of mouse spleen and its tissue distribution. J Biol Chem. 1969, 244: 5403-5413.PubMedGoogle Scholar
- Lindsey-Boltz LA, Wauson EM, Graves LM, Sancar A: The human Rad9 checkpoint protein stimulates the carbamoyl phosphate synthetase activity of the multifunctional protein CAD. Nucleic Acids Res. 2004, 32: 4524-4530. 10.1093/nar/gkh789.PubMed CentralView ArticlePubMedGoogle Scholar
- Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998, 27: 14484-14494.View ArticleGoogle Scholar
- Smith TF, Gaitatzes C, Saxena K, Neer EJ: The WD repeat: a common architecture for diverse functions. Trends Biochem Sci. 1999, 24: 181-185. 10.1016/S0968-0004(99)01384-5.View ArticlePubMedGoogle Scholar
- Kotsis DH, Masko EM, Sigoillot FD, Gregorio RD, Guy-Evans HI, Evans DR: Protein kinase A phosphorylation of the multifunctional protein CAD antagonizes activation by the MAP kinase cascade. Mol Cell Biochem. 2007, 301: 69-81. 10.1007/s11010-006-9398-x.View ArticlePubMedGoogle Scholar
- Morin A, Fritsch L, Mathieu JR, Gilbert C, Guarmit B, Firlej V, Gallou-Kabani C, Vieillefond A, Delongchamps NB, Cabon F: Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence. FASEB J. 2012, 26: 460-467. 10.1096/fj.11-191296.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.